Tesaro licenses rolapitant China rights to Hengrui

Tesaro Inc. (NASDAQ:TSRO) licensed exclusive Chinese rights for its lead candidate, oral rolapitant ( SCH 619734), to Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276). FDA accepted an NDA for rolapitant to prevent chemotherapy-induced nausea and vomiting (CINV) in November; the PDUFA date is Sept. 5.

Tesaro declined to disclose the financial details of the agreement, but said Hengrui will be responsible for all development, registration and commercialization activities in China. Tesaro will receive an undisclosed upfront payment, as well as milestones and royalties on net rolapitant sales in China. ...